Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, Dimer

Pancreatic Ductal Adenocarcinoma

OHSU Knight Cancer Institutemonoclonal_antibodyPhase 2Active

66/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 52/ 100
Competitive Position: 89/ 100

Competitive context

279 Active assets in the Pancreatic Ductal Adenocarcinoma cohort.

Asset / Sponsor	Phase	Rating
Rmc-6236 Tango Therapeutics, Inc.	Phase 3	BB
Daraxonrasib Revolution Medicines, Inc.	Phase 3	BB
S-1 Genentech, Inc.	Phase 2	BB
Metformin British Columbia Cancer Agency	Phase 2	BB
Xaliplatin Jonsson Comprehensive Cancer Center	Phase 4	BB

View all 50 →

Same molecule, other indications

Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, Dimer is also rated in:

malignant pancreatic neoplasmActive

Indicative · Phase 2

68 / 100

View asset →

biliary tract neoplasmDormant

Indicative · Phase 2

66 / 100

View asset →

Her2-receptor negative breast cancerDormant

Indicative · Phase 2

64 / 100

View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →